Chronic Kidney Disease

A study comparing patients with and those without type 2 diabetes found patients with diabetes had significantly higher rates of AKI than those without the condition.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, discusses challenges of anemia management in CKD.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, discussed treatment approaches for patients at risk for cardiovascular complications.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis discusses exciting new agents in the pipeline which may have a ‘significant impact' on how physicians approach patients with CKD.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, discussed needs for improvement in practice, including treatment of anemia patients with chronic kidney disease among patients who are not yet on dialysis.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, spoke with Healio on the relationship between anemia and quality of life in patients with chronic kidney disease.

Trials of SGLT2 inhibitors and GLP-1 receptor agonists, typically treatments for type 2 diabetes, have demonstrated potential CV and kidney benefits , according to a scientific statement from the American Heart Association.

Using the Kidney Disease: Improving Global Outcomes criteria, researchers found patients with type 2 diabetes who were at higher risk for adverse cardiovascular and kidney outcomes reaped the most benefits from canagliflozin.

Improved potassium levels impacted the physical and/or mental well-being of patients managing hyperkalemia, according to study results presented at the American Nephrology Nurses Association National Symposium.

Healio and Cardiology Today have compiled a list of the most-read news from the virtual European Society of Cardiology Congress.